Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing auto‐HSCT: An open‐label, multicenter, randomized phase 3 trial
暂无分享,去创建一个
Zhi-xiang Wang | F. Huang | L. Xuan | Zhiqiang Sun | Z. Fan | Jing Sun | Pengcheng Shi | D. Lin | N. Xu | Hui Liu | Jun Xu | Yu Zhang | Y. Xiong | R. Lin | Xudong Li | Qi-fa Liu | P. Shi | Xiao-fang Li | Xiaodan Liu | Mei-qing Wu